Experimental Hematology and Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice
This study provides evidence for the clinical observation that the abundance of GATA1s correlates well with the progression to AMKL in Down syndrome. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 26, 2024 Category: Cancer & Oncology Source Type: research

Strain-dependent modifiers exacerbate familial leukemia caused by GATA1-deficiency
AbstractGATA1 plays a critical role in differentiation, proliferation, and apoptosis during erythropoiesis. We developed aGata1 knock-down allele (Gata1.05) that results in GATA1 expression at 5% of endogenous level. In female mice heterozygous for both theGata1.05 and wild-type alleles, we observed a predisposition to erythroblastic leukemia three to six months after birth. Since no maleGata1.05 progeny survive gestation, we originally maintained heterozygous females in a mixed genetic background of C57BL/6J and DBA/2 strains. Around 30% of these mice reproducibly develop leukemia, but the other subset did not develop leu...
Source: Experimental Hematology and Oncology - February 26, 2024 Category: Cancer & Oncology Source Type: research

Challenges and strategies associated with CAR-T cell therapy in blood malignancies
AbstractCellular immunotherapy, particularly CAR-T cells, has shown potential in the improvement of outcomes in patients with refractory and recurrent malignancies of the blood. However, achieving sustainable long-term complete remission for blood cancer remains a challenge, with resistance and relapse being expected outcomes for many patients. Although many studies have attempted to clarify the mechanisms of CAR-T cell therapy failure, the mechanism remains unclear. In this article, we discuss and describe the current state of knowledge regarding these factors, which include elements that influence the CAR-T cell, cancer ...
Source: Experimental Hematology and Oncology - February 24, 2024 Category: Cancer & Oncology Source Type: research

Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies
AbstractNatural killer (NK) cell belongs to innate lymphoid cell family that contributes to host immunosurveillance and defense without pre-immunization. Emerging studies have sought to understand the underlying mechanism behind NK cell dysfunction in tumor environments, and provide numerous novel therapeutic targets for tumor treatment. Strategies to enhance functional activities of NK cell have exhibited promising efficacy and favorable tolerance in clinical treatment of tumor patients, such as immune checkpoint blockade (ICB), chimeric antigen receptor NK (CAR-NK) cell, and bi/trispecific killer cell engager (BiKE/TriKE...
Source: Experimental Hematology and Oncology - February 23, 2024 Category: Cancer & Oncology Source Type: research

Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma
ConclusionsCirrhotic-ECM modulated a NETs enriched TME in HCC, produced an immune suppressive TME and weakened ICI efficiency. Col1 receptor DDR1 could be a potential target synergically used with ICI to overcome ECM mediated ICI resistance. These provide a mechanical insight and novel strategy to overcome the ICI resistance of HCC. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 22, 2024 Category: Cancer & Oncology Source Type: research

Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia
ConclusionsOur study first identify vulnerability to ferroptosis by regulating MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway. Combined treatment with HMAs and FINs provides a potential therapeutic choice for AML patients, especially for R/R-AML. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 20, 2024 Category: Cancer & Oncology Source Type: research

Blockade of the lncRNA-DOT1L-LAMP5 axis enhances autophagy and promotes degradation of MLL fusion proteins
ConclusionsThe findings underscore the significance of LAMP5-AS1 in MLL leukemia progression through the regulation of the autophagy pathway. Additionally, this study unveils the novel lncRNA-DOT1L-LAMP5 axis as promising therapeutic targets for degrading MLL fusion proteins. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 19, 2024 Category: Cancer & Oncology Source Type: research

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
AbstractPatients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venetoclax (VEN) with hypomethylating agents has been established as the standard treatment for elderly or medically unfit AML patients unable to undergo intensive chemotherapy. Despite this, the availability of novel VEN-based therapies specifically tailored for those with R/R AML remains scarce. Here, we provide a comprehensive overview of the latest data presented at the 65th American Society of Hematology Annual Meeting, shedding lig...
Source: Experimental Hematology and Oncology - February 16, 2024 Category: Cancer & Oncology Source Type: research